Aurinia Pharmaceuticals (AUPH) Tops Q1 EPS by 7c ;Offers Guidance

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q1 EPS of ($0.18), $0.07 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $34.4 million versus the consensus estimate of $28.12 million.

GUIDANCE:

Aurinia Pharmaceuticals sees FY2023 revenue of $135-155 million, versus the consensus of $142.7 million.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• Kura Sushi (KRUS) Tops Q3 EPS by 3c; offers outlook
• Aurinia starts Phase 4 study combining Lupkynis with other lupus drugs
• Atoss Software (AOF:GR) PT Lowered to EUR135 at Berenberg